- Home
- EYPT vs DCTH Comparison
EYPT vs DCTH Comparison
Compare EYPT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- DCTH
- Stock Information
- Founded
- EYPT 1987
- DCTH 1988
- Country
- EYPT United States
- DCTH United States
- Employees
- EYPT N/A
- DCTH N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- DCTH Medical/Dental Instruments
- Sector
- EYPT Industrials
- DCTH Health Care
- Exchange
- EYPT Nasdaq
- DCTH Nasdaq
- Market Cap
- EYPT 489.4M
- DCTH 518.0M
- IPO Year
- EYPT 2005
- DCTH N/A
- Fundamental
- Price
- EYPT $6.15
- DCTH $14.88
- Analyst Decision
- EYPT Strong Buy
- DCTH Strong Buy
- Analyst Count
- EYPT 8
- DCTH 4
- Target Price
- EYPT $25.71
- DCTH $22.25
- AVG Volume (30 Days)
- EYPT 886.1K
- DCTH 356.0K
- Earning Date
- EYPT 03-06-2025
- DCTH 03-06-2025
- Dividend Yield
- EYPT N/A
- DCTH N/A
- EPS Growth
- EYPT N/A
- DCTH N/A
- EPS
- EYPT N/A
- DCTH N/A
- Revenue
- EYPT $45,713,000.00
- DCTH $22,644,000.00
- Revenue This Year
- EYPT N/A
- DCTH $1,672.40
- Revenue Next Year
- EYPT N/A
- DCTH $116.33
- P/E Ratio
- EYPT N/A
- DCTH N/A
- Revenue Growth
- EYPT 7.50
- DCTH 945.91
- 52 Week Low
- EYPT $5.90
- DCTH $3.70
- 52 Week High
- EYPT $29.31
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- EYPT 36.22
- DCTH 46.47
- Support Level
- EYPT $5.90
- DCTH $15.50
- Resistance Level
- EYPT $6.67
- DCTH $16.43
- Average True Range (ATR)
- EYPT 0.71
- DCTH 0.72
- MACD
- EYPT -0.04
- DCTH -0.25
- Stochastic Oscillator
- EYPT 8.99
- DCTH 2.79
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.